The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of durvalumab and tremelimumab together with radiotherapy for the adjuvant treatment of intermediate-risk head and neck squamous cell carcinoma.
 
Siddharth Sheth
No Relationships to Disclose
 
Bhishamjit S. Chera
No Relationships to Disclose
 
Benjamin Garrett Vincent
Leadership - Select Immunogenomics
Consulting or Advisory Role - NanoString Technologies
Research Funding - Merck; Merck
 
Colette J. Shen
No Relationships to Disclose
 
Mark Christian Weissler
Stock and Other Ownership Interests - Allergan; Baxter; Becton Dickinson; cardinal health; Express Scripts; Johnson & Johnson; Medtronic; Merck; Novartis; Pfizer; Procter & Gamble; Stryker; Walgreens; Zimmer
 
Jeffrey Blumberg
No Relationships to Disclose
 
Samip Patel
No Relationships to Disclose
 
Adam M. Zanation
No Relationships to Disclose
 
Wendell Gray Yarbrough
No Relationships to Disclose
 
Shetal Arvind Patel
No Relationships to Disclose
 
Juneko E. Grilley-Olson
Research Funding - Genentech (Inst); MedImmune (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Trevor Hackman
Consulting or Advisory Role - Liquidia Technologies
 
Jared Weiss
Stock and Other Ownership Interests - Nektar
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; BioMarck Pharmaceuticals; Celgene; EMD Serono; Genentech; Inivata
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Celgene (Inst); Merck (Inst); novartis (Inst); Pfizer (Inst)